Nucleus Software Exports Limited (NSE:NUCLEUS)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 1, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	27,191	21,109	31,658	17,095	11,106	13,986
Market Cap Growth	-17.26%	-33.32%	85.19%	53.93%	-20.59%	172.01%
Enterprise Value	23,622	17,925	27,553	13,568	6,289	9,757
Last Close Price	1015.70	794.21	1162.13	621.29	395.27	455.18
PE Ratio	16.19	12.95	16.52	13.38	27.15	11.86
PS Ratio	3.17	2.54	3.83	2.69	2.23	2.72
PB Ratio	3.34	2.59	4.07	2.80	2.25	2.08
P/TBV Ratio	3.34	2.60	4.08	2.81	2.28	2.09
P/FCF Ratio	-	15.55	16.37	37.05	33.22	12.50
P/OCF Ratio	-	13.99	14.26	34.30	19.26	12.17
EV/Sales Ratio	2.75	2.15	3.33	2.14	1.26	1.90
EV/EBITDA Ratio	13.64	10.91	12.79	9.19	21.38	7.94
EV/EBIT Ratio	14.58	11.68	13.39	9.83	29.05	8.45
EV/FCF Ratio	-	13.21	14.25	29.41	18.81	8.72
Debt / Equity Ratio	0.00	0.00	0.01	0.01	0.01	0.01
Debt / EBITDA Ratio	0.01	0.01	0.02	0.04	0.07	0.05
Debt / FCF Ratio	-	0.02	0.02	0.14	0.07	0.06
Asset Turnover	-	0.73	0.83	0.79	0.61	0.62
Quick Ratio	-	1.83	2.00	2.00	2.03	3.05
Current Ratio	-	1.93	2.07	2.08	2.09	3.11
Return on Equity (ROE)	-	20.48%	27.61%	23.14%	7.02%	19.13%
Return on Assets (ROA)	-	8.47%	12.94%	10.71%	1.67%	8.76%
Return on Capital (ROIC)	12.44%	12.01%	18.39%	15.50%	2.31%	11.59%
Return on Capital Employed (ROCE)	-	17.60%	25.10%	21.50%	4.20%	16.80%
Earnings Yield	6.18%	7.72%	6.05%	7.47%	3.68%	8.43%
FCF Yield	-	6.43%	6.11%	2.70%	3.01%	8.00%
Dividend Yield	1.23%	1.57%	1.08%	1.61%	1.77%	1.98%
Payout Ratio	-	20.53%	13.97%	14.67%	42.58%	7.38%
Buyback Yield / Dilution	1.25%	0.84%	-	6.53%	1.37%	-
Total Shareholder Return	2.48%	2.41%	1.08%	8.14%	3.14%	1.98%

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.